3 results
The overall goal of this RCT is to compare the efficacy of 90Y-RE to TACE-DEB, for patients with intermediate stage HCC. Time to progression, overall survival, tumor response, adverse events, treatment related effect on total liver function, quality…
Phase 1 - Primary Objective• To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single-agent MCLA-129 in patients with NSCLC, GC/GEJ adenocarcinoma, HNSCC or ESCC, with disease progression after prior therapy for…
The objective of the study is to evaluate TheraSphere in the treatment of patients with unresectablehepatocellular carcinoma in whom treatment with standard-of-care sorafenib therapy is planned.